About
Matricelf developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients Omentum biopsy. The platform showed remarkable pre-clinical results for several medical conditions. The company recently licensed the technology that enabled scientist at Tel Aviv university that 3D printed a human heart from human cells and matrix for the first time in human history. The company plans to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2024.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
25Traction
0Team
60Visibility
0Profile
50Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Matricelf do?
Matricelf developed a technology that enables the production of autologous engineered tissue composed of matrix and cells derived from patients Omentum biopsy. The platform showed remarkable pre-clinical results for several medical conditions. The company recently licensed the technology that enabled scientist at Tel Aviv university that 3D printed a human heart from human cells and matrix for the first time in human history. The company plans to conduct its first human clinical trial for Acute…
When was Matricelf founded?
Matricelf was founded in 2019.
What industry does Matricelf operate in?
Matricelf operates in Life Sciences, Biotech.
What is Matricelf's current status?
Matricelf's current operating status is: Public.